RSA Viewpoints
The UK is a leader in life sciences. How can we make sure that it remains No.1 in Europe?
After spending a day in mid-October at this year’s excellent UK BioScience Forum, I was left with one particular thought ringing loud and clear...
How hiring the best leaders maximizes biotech exit values
We’ve seen some major exits in the biotech market in 2017. Early in the year, in Switzerland alone, Actelion was sold to Johnson &...
Recruitment International | The key to success in life sciences
Alex Bennett, CEO of The RSA Group, discusses the current opportunities and leadership challenges in the life sciences sector – and how to succeed...
RSA Viewpoint | The Successful Leader
There’s no doubt the leader’s job is becoming increasingly difficult in today’s environment. We’re experiencing unprecedented levels of change – societal, political, economic and...
Engaging with executive interims – time for a fresh perspective
Habits are hard to break and all too often we return to established patterns of behaviour rather than looking for innovative ways to do...
Diversity: A call to arms for Biotech Leaders and Investors
A panel discussion, led by The RSA Group, at the recent BIA UK CEO & Investor Forum discussed the demographic time bomb facing biotech boards...
The value of engaging Pharmacoeconomic executive interims
So what is Pharmacoeconomics? Pharmacoeconomics, is the “scientific discipline which evaluates the clinical, economic and humanistic aspects of pharmaceutical products, services, and programmes, as...
Pharmaceutical Market Europe | Massive Uncertainty is the new norm
There’s a lot of change coming: changes of practice, thinking and behaviour, all of which represent challenge and opportunity. Those leaders who recognise it...
Hiring international executives and the (true) costs of failure
A tale of two …points of view? “It was the best of times, it was the worst of times, it was the age of...
Building talent and saving lives
London was the setting last week for the 25th Annual Meeting of the International Society for Cellular Therapy. The huge increase of clinical trials...
RSA Talent Equity® | Biotech IPOs and Deals 2016
In our latest Talent Equity® Report, we examine the performance of biotech leaders whose companies IPO’d or were active in deal-making in 2016. Leaders...
A Report from BIO-Europe Spring 2017
The blue skies and balmy weather of Barcelona were the perfect backdrop for BIO-Europe Spring this year. The 2,400 biotech pros at the conference...
Behavioural profiling in the search for medical affairs professionals
In pharmaceutical companies, medical affairs professionals play a vital yet complex role: acting as a bridge between the medical and commercial groups, and as...
Report from J.P. Morgan 2017
So, that’s the J.P. Morgan Healthcare Conference done for another year. For just a few highly energised days it felt as if nearly every...
A report from the 2018 J.P.Morgan Healthcare Conference
A quiet JPM18? I don’t think so. One thing I learned at JPM18 was that journalists see the world differently to me. There were...